Ulcerative colitis (N=546) | Crohn's disease (N=357) | Total (N=903) | |
---|---|---|---|
5-ASA or SASP | 486 (89.0%) | 276 (77.3%) | 762 (84.4%) |
PSL | 79 (9.0%) | 26 (7.3%) | 105 (11.6%) |
(mg) | (1–60) | (1–40) | |
AZA or 6-MP | 56 (10.3%) | 55 (15.4%) | 111 (12.3%) |
(mg) | (15–100) | (10–100) | |
Tacrolimus | 4 (0.7%) | – | 4 (0.4%) |
IFX | 18 (3.3%) | 151 (42.3%) | 169 (1807%) |
(mg) | (200–500) | (150–500) | |
ADA | – | 11 (3.1%) | 11 (1.2%) |
TPN | 0 (0.0%) | 3 (0.8%) | 3 (0.3%) |
ED | 70 (19.6%) | 70 (7.8%) | |
(kcal/day) | (300–1,800) | ||
CAP | 3 (0.5%) | 1 (0.3%) | 4 (0.4%) |
5-ASA, aminosalicilic acid; ADA, adalimumab; AZA, azathioprine; CAP, cytoapheresis; ED, elemental diet; IFX, infliximab; MP, mercaptopurine; PSL, prednisolone; SASP, salazosurufapirizine; TPN, total parenteral nutrition.